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ARTICLE
Neurochemical evidence of astrocytic and
neuronal injury commonly found in COVID-19
Nelly Kanberg, MD, Nicholas J. Ashton, PhD, Lars-Magnus Andersson, MD, PhD, Aylin Yilmaz, MD, PhD,
Magnus Lindh, MD, PhD, Staffan Nilsson, PhD, Richard W. Price, MD, PhD, Kaj Blennow, MD, PhD,







To test the hypothesis that coronavirus disease 2019 (COVID-19) has an impact on the CNS
by measuring plasma biomarkers of CNS injury.
Methods
We recruited 47 patients with mild (n = 20), moderate (n = 9), or severe (n = 18) COVID-19
and measured 2 plasma biomarkers of CNS injury by single molecule array, neurofilament light
chain protein (NfL; a marker of intra-axonal neuronal injury) and glial fibrillary acidic protein
(GFAp; a marker of astrocytic activation/injury), in samples collected at presentation and again
in a subset after a mean of 11.4 days. Cross-sectional results were compared with results from 33
age-matched controls derived from an independent cohort.
Results
The patients with severe COVID-19 had higher plasma concentrations of GFAp (p = 0.001)
and NfL (p < 0.001) than controls, while GFAp was also increased in patients with moderate
disease (p = 0.03). In patients with severe disease, an early peak in plasma GFAp decreased on
follow-up (p < 0.01), while NfL showed a sustained increase from first to last follow-up (p <
0.01), perhaps reflecting a sequence of early astrocytic response andmore delayed axonal injury.
Conclusion
We show neurochemical evidence of neuronal injury and glial activation in patients with
moderate and severe COVID-19. Further studies are needed to clarify the frequency and nature
of COVID-19–related CNS damage and its relation to both clinically defined CNS events such
as hypoxic and ischemic events and mechanisms more closely linked to systemic severe acute
respiratory syndrome coronavirus 2 infection and consequent immune activation, as well as to
evaluate the clinical utility of monitoring plasma NfL and GFAp in the management of this
group of patients.
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Early in the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) outbreak, a case series from Wuhan, China,
reported CNS involvement in 36% of patients hospitalized for
severe coronavirus disease 2019 (COVID-19) infection.1 CNS
involvement was previously described in hospitalized patients
infected with severe acute respiratory syndrome coronavirus
(SARS-CoV) during the 2003 to 2004 SARS epidemic.2 Fur-
thermore, SARS-CoV was isolated from brain tissue with
edema and neuronal degeneration at autopsy, confirming viral
infection of the neurons.2,3 Given the taxonomic similarity
between SARS-CoV and SARS-CoV-2, it is plausible that
patients with COVID-19 might also exhibit CNS damage re-
lated to the infecting coronavirus. It remains unclear to what
extent SARS-CoV-2 is able to infect the CNS and, if it does,
how the virus reaches the brain, but 2 possible theories have
emerged: spread across the cribriform plate of the ethmoid
bone in proximity to the olfactory bulb in patients at the early
stage of the disease, resulting in the relatively common loss of
sense of smell,4 or a later-occurring hematogenous spread on
the setting of accompanied hypoxia, respiratory, and metabolic
acidosis.5 Direct CNS infection by SARS-CoV has also been
shown in mice,6 but whether SARS-CoV-2 infects the brain of
humans remains unknown.
To assess the broad impact of COVID-19 on CNS and to test
the hypothesis that COVID-19 is accompanied by un-
derappreciated CNS injury, we analyzed 2 plasma biomarkers
for CNS injury (glial fibrillary acidic protein [GFAp] and
neurofilament light chain protein [NfL]) in patients with
COVID-19 and matched controls. GFAp is an intermediate
filament, is highly expressed in astrocytes, and serves as
a marker of astrocytic activation/injury.7 NfL is an intra-axonal
structural protein and a biomarker of neuronal injury.8 While
extensively studied in CSF, recent sensitive methods have
shown that plasma measurement of both biomarkers reliably
detects CNS injury and correlates with clinical outcomes in
a range of conditions.8 The aim of this studywas to examine the
extent of CNS involvement in patients with COVID-19 as




Forty-seven patients with confirmed COVID-19 were divided
into 3 groups related to systemic disease severity: 20 patients
with mild (i.e., not requiring hospitalization), 9 with moderate
(hospitalized and requiring oxygen supplementation), and 18
with severe (admitted to the intensive care unit [ICU] and
placed on mechanical ventilation [n = 17] or not considered
a candidate for ICU treatment and with fatal outcome [n = 1])
disease. The biomarker findings were compared to those of
age-matched controls (n = 33) who were initially recruited as
cognitively unimpaired controls for an observational study on
risk factors for neurodegeneration. None of them had psychi-
atric or neurologic comorbidity, and any MRI abnormalities
were set as an exclusion criterion.
Blood samples were collected from a subgroup of patients at
a mean (SD) of 13.0 (7.37) days after onset of symptoms
(16.0 [9.85] days in mild, 11.6 [2.19] days in moderate, and
10.4 [4.35] days in severe disease). In 31 of the patients,
follow-up specimens were collected up to amean (SD) of 11.4
(5.06) days after the first sampling. Follow-up samples on
patients with severe COVID-19 were collected during on-
going ICU hospitalization.
Viral diagnostic methods
The diagnosis of SARS-CoV-2 infection was confirmed with
real-time PCR analysis of nasal and throat swab specimens.
Nucleic acid was extracted from clinical samples in a MagNA
Pure 96 instrument using the Total Nucleic Acid isolation kit
(Roche, Basel, Switzerland). Real-time PCR targeting the
RNA-dependent RNA polymerase (RdRP) region was per-
formed in a QuantStudio 6 instrument (Applied Biosystems,
Foster City, CA) using the probe described elsewhere and the
primers RdRP_Fi, GTCATGTGTGGCGGTTCACT and
RdRP_Ri, CAACACTATTAGCATAAGCAGTTGT.9
Biomarker analyses
All plasma GFAp and NfL measurements were performed in
the Clinical Neurochemistry Laboratory at the Sahlgrenska
University Hospital by board-certified laboratory technicians
blinded to clinical data using commercially available single
molecule array assays on an HD-X Analyzer (Human Neu-
rology 4-Plex A assay (N4PA advantage kit, 102,153), as de-
scribed by the manufacturer (Quanterix, Billerica, MA). A
single batch of reagents was used; intra-assay coefficients of
variation were <10% for all analytes. Because in acute brain
injury plasmaGFAp increases rapidly and has a short half-life of
24 to 48 hours while plasma NfL increases later and remains
elevated for >10 days,10 for patients with multiple sampling
available, we used the first sample for GFAp and the last forNfL
in cross-sectional comparisons between groups.
Statistical analyses
All data are reported as mean and SD unless otherwise in-
dicated. Associations were measured with the Pearson corre-
lation. Estimated geometric means at 70 years of age were
Glossary
CI = confidence interval; COVID-19 = coronavirus disease 2019; GFAp = glial fibrillary acidic protein; ICU = intensive care
unit; IQR = interquartile range; NfL = neurofilament light chain protein; RdRP = RNA-dependent RNA polymerase; SARS-
CoV = severe acute respiratory syndrome coronavirus; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.
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compared between the 3 COVID-19 groups and controls by
analyzing log10 plasma levels with analysis of covariance with
adjustment for age and including interactions between age and
group. Changes in log concentrations from the first to last
measure were analyzed with paired t tests. A value of p < 0.05
was considered significant. Analyses results and graphs were
generated with SPSS statistics (IBM SPSS version 25, Chicago,
IL) or Prism (GraphPad Software version 8.00, La Jolla, CA).
Standard protocol approvals, registrations,
and patient consents
This study was approved by the Swedish Ethical Review
Authority (2020-01771). All participants provided informed
consent. For those with severe COVID-19, consent was
obtained before they were placed on mechanical ventilation;
they were deemed fully capable of understanding the nature of
the study and their part in it.
Data availability
Researchers can apply for access to anonymized data from the
present study for well-defined research questions that are in
line with the overall research agenda for the cohort. Please
contact the corresponding author.
Results
Demographics
All patients had a confirmed SARS-CoV-2 infection. Those in
the mild group were generally younger and otherwise healthy,
while the moderate and severe patients were mostly men, were
older, and had more comorbid conditions (table 1). The
control group consisted of 16 women and 17 men with a me-
dian (interquartile range [IQR]) age of 67.0 (42.3–77.8) years.
Four patients had symptoms of confusion before admission to
the ICU, and 1 patient had a single episode of seizure before
transfer to the ICU with no signs of epileptic activity at EEG
performed the day after. CT scans were normal in 2 of the 3
cases scanned; the third had signs of small vessel disease. MRI
scans were not performed due to restrictions imposed by the
protection of hospital workers and other patients in place at the
time. No additional neurologic abnormalities were documented.
Biomarkers
Both plasma GFAp (r = 0.62, p < 0.001) and NfL (r = 0.62, p <
0.001) were correlated with age for patients with COVID-19
and controls (figure 1, A and B). Concentrations of GFAp and
NfL in the different subgroups are given in table 2. Patients with
severe COVID-19 had significantly higher plasma concen-
trations of GFAp (p = 0.001) and NfL (p < 0.001) than con-
trols; GFAp was increased also in patients with moderate
disease (p = 0.03, figure 1, A and B). Patients with severe
COVID-19 had 78% (95% confidence interval [CI]
27%–150%) higher plasma concentrations of GFAp (p =
0.001) and 208% (95% CI 120%–329%) higher NfL (p <
0.001) than controls when the estimated geometric means at
70 years of age were compared. Plasma GFAp was 56% (95%
CI 4%–133%) higher in patients with moderate disease com-
pared to controls (p = 0.03). A correlation was found between
plasma GFAp and NfL (r = 0.580, p < 0.001, figure 1C).
Neither plasmaGFAp, nor NfL changed significantly from the
initial to the last follow-up in patients with mild or moderate
disease (figure 2, A and C). In contrast, in the severe group,
plasma GFAp decreased from a median of 215 (IQR
106–281) pg/mL at the initial to 103 (IQR 60–225) pg/mL
at the last sampling (p = 0.004, figure 2B), and plasma NfL
Table 1 Patient characteristics
Total (n = 47) Mild (n = 20) Moderate (n = 9) Severe (n = 18)
Demographic characteristics
Age, median (IQR), y 57.8 (48.0–69.5) 55.6 (37.4–60.2) 67.5 (55.4–72.6) 58.0 (51.3–72.2)
Sex, n (%)
Female 15 (32) 10 (50) 3 (33) 2 (11)
Male 32 (68) 10 (50) 6 (67) 16 (89)
Comorbid conditions, n (%)
Any 18 (38) 1 (5) 5 (56) 12 (67)
Hypertension 12 (26) 0 2 (22) 10 (56)
Obesity 3 (6) 0 1 (11) 2 (11)
Diabetes mellitus 9 (19) 0 2 (22) 7 (39)
Coronary heart disease 7 (15) 1 (5) 2 (22) 4 (22)
Malignancy 1 (2) 0 0 1 (6)
Abbreviation: IQR = interquartile range.
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concentrations increased from a median of 20 (IQR 11–24)
pg/mL in the first to 32 (IQR 16–60) pg/mL in last specimen
(p = 0.002, figure 2D).
Plasma NfL concentration correlated inversely with the
blood lymphocyte count, a negative prognostic factor11 (r =
−0.37, p = 0.047); there was no significant correlation with
C-reactive protein concentrations (data not shown).
Discussion
We have examined 2 blood-based biomarkers for CNS injury in
patients with COVID-19. NfL andGFAp have historically been
proven to be useful measures of CNS injury when assessed in
CSF, but sampling of this fluid is challenging in the clinical
COVID-19 setting. In contrast, measurement of these markers
in the plasma is convenient and provides a practical method of
assessing the effect of COVID-19 on the CNS. This approach
follows extensive validation of their ability to detect CNS injury
in several conditions, including neurodegenerative disorders,
multiple sclerosis, HIV, and cardiac arrest.12–15
The results of this study indicate that astrocytic activation/
injury (GFAp measurements) may be a common feature in
moderate and severe stages of COVID-19, while neuronal
injury (NfL) occurs later in the disease process and mainly in
patients with severe disease. One may hypothesize that
astrocytic activation/injury is a first response to CNS insult
and that a plasma NfL increase reflects a progression to
neuronal injury in severe cases.
The pathogenesis of these CNS effects of COVID-19 is not
known, although direct invasion of the virus may be unlikely.
The entry of SARS-CoV-2 into human host cells is mediated
mainly by the cellular receptor angiotensin-converting enzyme
Table 2 Median (IQR) plasma concentrations of GFAp and NfL in different subgroups of COVID-19 and controls
Mild (n = 20) Moderate (n = 9) Severe (n = 18) Controls (n = 33)
Plasma GFAp concentrations, median (IQR), pg/mL 90.5 (53.5–139) 204 (158–341) 206 (106–308) 141 (108–207)
Plasma NfL concentrations, median (IQR), pg/mL 9.5 (5.1–12.2) 19.3 (12.1–22.6) 32.7 (19.3–56.3) 13.1 (9.4–21.0)
Abbreviations: COVID-19 = coronavirus disease 2019; GFAp = glial fibrillary acidic protein; IQR = interquartile range; NfL = neurofilament light chain protein.
Figure 1 Plasma concentrations of blood-based CNS biomarkers in patients with mild, moderate, and severe COVID-19
compared to healthy controls
(A and B) Log10 plasma levels were
analyzed with analysis of co-
variance, including interactions
between age and group. Estimated
geometric means at 70 years of
age for the 3 coronavirus disease
2019 (COVID-19) groups were
compared with controls. (A) Age
and plasma glial fibrillary acidic
protein (GFAp) were significantly
correlated. Plasma levels of GFAp
were significantly increased in the
moderate and severe COVID-19
groups compared to controls (p =
0.03 and p = 0.001, respectively).
(B) Age and plasma neurofilament
light chain protein (NfL) were sig-
nificantly correlated. Plasma levels
of NfL were 3.1 times higher in
patients with severe COVID-19
compared to controls (p < 0.001).
(C) Correlation between log10 val-
ues of plasma GFAp and NfL in
patients with COVID-19.
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2, which is expressed at very low levels in the CNS under
normal conditions.3 CNS hypoxia due to respiratory failure
caused by COVID-19, thrombotic microangiopathy, and an
indirect effect of the vigorous inflammatory response with ex-
tensive cytokine activation that is commonly found in severe
COVID-19 are more probable explanations, although further
study is needed to examine these factors.
Our study has several limitations. First, it included a limited
number of participants. Second, due to restrictions imposed to
isolate and protect personnel and equipment and because all
our severely ill patients were admitted to the ICU and on
mechanical ventilators, a thorough neurologic and cognitive
evaluation was not done, and long-term follow-ups were lim-
ited. In addition, fully accounting for the potential impact of
confounding factors such as vascular risk factors has not been
possible. None of the controls had any inadequately treated
condition, but data on treated comorbid conditions are lacking.
Our results show that plasma biomarkers of CNS damage are
increased in patients with COVID-19 and are associated with
disease severity. Further studies are needed to clarify the na-
ture of CNS injury in this setting and to further evaluate the
utility of these biomarkers in COVID-19.
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Figure 2 Plasma concentrations of GFAp and NfL in relation to onset of COVID-19 symptoms
Plasma glial fibrillary acidic protein
(GFAp) and neurofilament light
chain protein (NfL) concentrations
in patients with mild (green
squares), moderate (blue tri-
angles), and severe (red triangles)
coronavirus disease 2019 (COVID-
19). Lines connect multiple sam-
pling in individual patients. (A and
C) No significant changes from ini-
tial to last follow-up were found in
mild or moderate disease. (B and
D) In contrast, a significant de-
crease in plasma GFAp (p = 0.004)
and increase in plasma NfL (p =
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